New approaches for biomarker discovery in lung cancer

Lung cancer remains the most common cause of cancer death in the US and worldwide. Currently, there is no implemented population-based screening for lung cancer. Of all the markers identified, none have achieved sufficient diagnostic significance to reach clinical application. Here we discuss the status of lung cancer early diagnostics, and the genomic and proteomic approaches currently undertaken for biomarker discovery. We then introduce the ANTIBIOMIXTM approach that enables high-throughput target discovery by interrogating biological samples using a collection of thousands of polyclonal antibodies. The development of specific and sensitive diagnostic assays using patient’s biological fluids, such as sputum and serum, will improve screening, monitoring of disease progression and treatment response, and surveillance for recurrence.

[1]  U. Pastorino,et al.  Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients: a prospect for early diagnosis. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  W. Travis,et al.  The new World Health Organization classification of lung tumours , 2001, European Respiratory Journal.

[3]  Shigeki Shimizu,et al.  [Molecular abnormalities in lung cancer]. , 2002, Nihon rinsho. Japanese journal of clinical medicine.

[4]  E. Haura.  Treatment of advanced non-small-cell lung cancer: a review of current randomized clinical trials and an examination of emerging therapies. , 2001, Cancer control : journal of the Moffitt Cancer Center.

[5]  L. Liotta,et al.  Laser capture microdissection and microarray expression analysis of lung adenocarcinoma reveals tobacco smoking- and prognosis-related molecular profiles. , 2002, Cancer research.

[6]  David E. Misek,et al.  Discordant Protein and mRNA Expression in Lung Adenocarcinomas * , 2002, Molecular & Cellular Proteomics.

[7]  Patrick C. Walsh,et al.  American Cancer Society Guidelines for the Early Detection of Cancer , 2002, CA: a cancer journal for clinicians.

[8]  Juri Rappsilber,et al.  Mass spectrometry and EST-database searching allows characterization of the multi-protein spliceosome complex , 1998, Nature Genetics.

[9]  S. Reed,et al.  L552S, an alternatively spliced isoform of XAGE-1, is over-expressed in lung adenocarcinoma , 2001, Oncogene.

[10]  Michael Thomas,et al.  Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer. , 2002, Lung cancer.

[11]  J. Schiller,et al.  Current Standards of Care in Small-Cell and Non-Small-Cell Lung Cancer , 2001, Oncology.

[12]  Sharon L R Kardia,et al.  Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  O. Kallioniemi.  Biochip technologies in cancer research , 2001, Annals of medicine.

[14]  J. Minna,et al.  Molecular detection of early lung cancer. , 1999, Journal of the National Cancer Institute.

[15]  J. Nikliński,et al.  Molecular genetic abnormalities in premalignant lung lesions: biological and clinical implications , 2001, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[16]  T. Jacks,et al.  Modeling human lung cancer in mice: similarities and shortcomings , 1999, Oncogene.

[17]  A Coldman,et al.  Localization of bronchial intraepithelial neoplastic lesions by fluorescence bronchoscopy. , 1998, Chest.

[18]  E. Petricoin,et al.  Clinical proteomics: translating benchside promise into bedside reality , 2002, Nature Reviews Drug Discovery.

[19]  G. Strauss.  The Mayo Lung Cohort: a regression analysis focusing on lung cancer incidence and mortality. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  D. Weiner,et al.  p185neu expression in human lung adenocarcinomas predicts shortened survival. , 1990, Cancer research.

[21]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.

[22]  M. Tockman,et al.  Expression of early lung cancer detection marker: hnRNP-A2/B1 and its relation to microsatellite alteration in non-small cell lung cancer. , 2001, Lung cancer.

[23]  J. Mattick.  Non‐coding RNAs: the architects of eukaryotic complexity , 2001, EMBO reports.

[24]  W. Prime,et al.  Heterogeneous nuclear ribonucleoprotein A2/B1 up-regulation in bronchial lavage specimens: a clinical marker of early lung cancer detection. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  W. Fry,et al.  Ten‐year survey of lung cancer treatment and survival in hospitals in the United States , 1999, Cancer.

[26]  J. Herman,et al.  Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. , 1999, Journal of the National Cancer Institute.

[27]  M. Tockman.  Clinical detection of lung cancer progression markers , 1996, Journal of cellular biochemistry. Supplement.

[28]  E. Lai.  Micro RNAs are complementary to 3′ UTR sequence motifs that mediate negative post-transcriptional regulation , 2002, Nature Genetics.

[29]  E. Petricoin,et al.  Serum proteomic patterns for detection of prostate cancer. , 2002, Journal of the National Cancer Institute.

[30]  E. Fearon.  The smoking gun and the damage done: genetic alterations in the lungs of smokers. , 1997, Journal of the National Cancer Institute.

[31]  R. Stoughton,et al.  Experimental annotation of the human genome using microarray technology , 2001, Nature.

[32]  G. Strauss.  Prognostic markers in resectable non-small cell lung cancer. , 1997, Hematology/oncology clinics of North America.

[33]  J. Herman,et al.  Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. , 1999, Cancer research.

[34]  M. Tockman.  Lung cancer: chemoprevention and intermediate effect markers. , 2001, IARC scientific publications.

[35]  M. Tockman,et al.  New approaches to the integrated management of early lung cancer. , 1997, Hematology/oncology clinics of North America.

[36]  Ahmedin Jemal,et al.  Cancer Statistics, 2002 , 2002, CA: a cancer journal for clinicians.

[37]  G. Hannon.  RNA interference : RNA , 2002 .

[38]  J. J. Amaral-Mendes,et al.  Use of Biochemical and Molecular Biomarkers for Cancer Risk Assessment in Humans , 1999 .

[39]  A. Gazdar,et al.  Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  F. Hirsch,et al.  Epidermal growth factor receptor family in lung cancer and premalignancy. , 2002, Seminars in oncology.

[41]  R. Stahel,et al.  Biology of lung cancer. , 1994, Lung cancer.

[42]  A. Jeffreys,et al.  Hypervariable minisatellite DNA sequences in the Indian peafowl Pavo cristatus. , 1991, Genomics.

[43]  Paul Ahlquist,et al.  RNA-Dependent RNA Polymerases, Viruses, and RNA Silencing , 2002, Science.

[44]  L. Liotta,et al.  Laser-capture microdissection: opening the microscopic frontier to molecular analysis. , 1998, Trends in genetics : TIG.

[45]  E. Petricoin,et al.  An approach to proteomic analysis of human tumors , 2000, Molecular carcinogenesis.

[46]  Minetta C. Liu,et al.  P53 gene mutations: case study of a clinical marker for solid tumors. , 2002, Seminars in oncology.

[47]  F. Hirsch,et al.  Expression of target molecules in lung cancer: challenge for a new treatment paradigm. , 2002, Seminars in oncology.

[48]  S. Sone,et al.  Results of three-year mass screening programme for lung cancer using mobile low-dose spiral computed tomography scanner , 2001, British Journal of Cancer.

[49]  S. Gygi,et al.  Correlation between Protein and mRNA Abundance in Yeast , 1999, Molecular and Cellular Biology.

[50]  S. Swensen,et al.  Screening for lung cancer with low-dose spiral computed tomography. , 2000, American journal of respiratory and critical care medicine.

[51]  R. Kuick,et al.  A database of protein expression in lung cancer , 2001, Proteomics.

[52]  A. Vlahou,et al.  Proteomic approaches to biomarker discovery in prostate and bladder cancers , 2001, Proteomics.

[53]  D. Flieder,et al.  Small peripheral glandular lesions detected by screening CT for lung cancer. A diagnostic dilemma for the pathologist. , 2000, Radiologic clinics of North America.

[54]  K. Braithwaite,et al.  Multi-step evolution of lung cancer. , 1999, Seminars in cancer biology.

[55]  A. Kaur,et al.  Analysis of the human neurexin genes: alternative splicing and the generation of protein diversity. , 2002, Genomics.

[56]  O. Miettinen,et al.  Early Lung Cancer Action Project: overall design and findings from baseline screening , 1999, The Lancet.

[57]  J. Mulshine,et al.  Purification and Characterization of a Protein That Permits Early Detection of Lung Cancer , 1996, The Journal of Biological Chemistry.

[58]  S. Hanash,et al.  A Proteomic Approach to the Identification of Lung Cancer Markers , 2002, Disease markers.

[59]  J. Jett.  Screening for lung cancer: no longer a taboo subject. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  J. Herman,et al.  Predicting lung cancer by detecting aberrant promoter methylation in sputum. , 2000, Cancer research.

[61]  Bosiljka Tasic,et al.  Alternative pre-mRNA splicing and proteome expansion in metazoans , 2002, Nature.

[62]  S. P. Fodor,et al.  Large-Scale Transcriptional Activity in Chromosomes 21 and 22 , 2002, Science.

[63]  M. Thun,et al.  Cigarette smoking and changes in the histopathology of lung cancer. , 1997, Journal of the National Cancer Institute.

[64]  Robert J Cerfolio,et al.  Differential expression and biodistribution of cytokeratin 18 and desmoplakins in non-small cell lung carcinoma subtypes. , 2002, Lung cancer.

[65]  David E. Misek,et al.  Gene-expression profiles predict survival of patients with lung adenocarcinoma , 2002, Nature Medicine.